EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson’s Disease Psychosis

Fernando L Pagan iD, Paul E Schulz iD, Yasar Torres-Yaghi iD, Gregory M Pontone iD

CNS Drugs · 2024

DOI: 10.1007/s40263-024-01084-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Drugs, 2024. Verfasst von Fernando L Pagan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Georgetown University Hospital, Washington DC, USA. Hauptthemen laut MEDLINE: Parkinson Disease, Psychotic Disorders, Antipsychotic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ACADIA Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson's disease (PD) is associated with the development of psychosis (PDP), including hallucinations and delusions, in more than half of the patient population. Optimal PD management must therefore involve considerations about both motor and non-motor symptoms. Often, clinicians fail to diagnosis psychosis in patients with PD and, when it is recognized, treat it suboptimally, despite the availability of multiple interventions. In this paper, we provide a summary of the current guidelines and clinical evidence for treating PDP with antipsychotics. We also provide recommendations for diagnosis and follow-up. Finally, an updated treatment algorithm for PDP that incorporates the use of pimavanserin, the only US FDA-approved drug for the treatment of PDP, was developed by extrapolating from a limited evidence base to bridge to clinical practice using expert opinion and experience. Because pimavanserin is only approved for the treatment of PDP in the US, in other parts of the world other recommendations and algorithms must be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseasePsychotic DisordersAntipsychotic AgentsHumansHallucinationsPiperidinesUrea

Substanzen

pimavanserinPiperidinesAntipsychotic AgentsUrea

Autor:innen und Institutionen

  • Department of Neurology, Georgetown University Hospital, Washington DC, USA.
  • Department of Neurology, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 600 N Wolfe St., Phipps 300, Baltimore, MD, 21287, USA. gpontone@jhmi.edu.
  • Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. gpontone@jhmi.edu.

ORCID-Profile: Fernando L Pagan, Paul E Schulz, Yasar Torres-Yaghi, Gregory M Pontone

Förderung

  • ACADIA Pharmaceuticals

Zitieren

APA

Pagan, F. L., Schulz, P. E., Torres-Yaghi, Y., & Pontone, G. M. (2024). On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson’s Disease Psychosis. CNS Drugs. https://doi.org/10.1007/s40263-024-01084-1

Vancouver

Pagan FL, Schulz PE, Torres-Yaghi Y, Pontone GM. On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson’s Disease Psychosis. CNS Drugs. 2024. doi:10.1007/s40263-024-01084-1

BibTeX
@article{Pagan2024,
  author = {Pagan, Fernando L and Schulz, Paul E and Torres-Yaghi, Yasar and Pontone, Gregory M},
  title = {On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson’s Disease Psychosis},
  journal = {CNS Drugs},
  year = {2024},
  doi = {10.1007/s40263-024-01084-1}
}
Kostenlos starten →